Journal of Hematology & Oncology is the official journal of the Chinese American Hematologist and Oncologist Network.
Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents
Patients with higher-risk myelodysplastic syndromes (MDS) refractory to hypomethylating agents (HMAs) have limited therapeutic options and an expected overall survival (OS) of 3–5 months. Eltanexor is an inves...